TODD M BAUER
Allopathic & Osteopathic Physicians|Internal Medicine|Hematology & Oncology NASHVILLE, TN NPI 1336296136
Browse related groups: Allopathic & Osteopathic Physicians|Internal Medicine|Hematology & Oncology TN PFIZER INC. All categories
General Payments — all program years on this page
$351,518.53
- Category: General Payments
- Program years: PY2018–2024
- Record count: 418
- As of (CMS publication): 2026-01-23
Latest program year (PY2024): $35,722.60 across 66 records · disputed records: 0
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How this figure is calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
Latest program year (PY2024) · sorted by reported total.
| Nature of payment | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $21,547.00 | 7 |
| Consulting Fee | $9,128.00 | 4 |
| Travel and Lodging | $3,149.57 | 6 |
| Food and Beverage | $1,878.03 | 48 |
| Education | $20.00 | 1 |
By paying entity
Latest program year (PY2024) · sorted by reported total.
| Paying entity | Amount | Records |
|---|---|---|
| PFIZER INC. | $27,645.57 | 27 |
| Bayer HealthCare Pharmaceuticals Inc. | $6,188.00 | 2 |
| Tempus AI, Inc | $750.00 | 1 |
| Daiichi Sankyo Inc. | $203.37 | 7 |
| ABBVIE INC. | $140.62 | 2 |
| Genmab U.S., Inc. | $125.00 | 1 |
| Amgen Inc. | $90.85 | 1 |
| Celgene Corporation | $77.88 | 3 |
| NOVARTIS PHARMACEUTICALS CORPORATION | $73.34 | 3 |
| Regeneron Healthcare Solutions, Inc. | $48.85 | 2 |
| Pharmacosmos Therapeutics Inc. | $39.10 | 2 |
| Dendreon Pharmaceuticals LLC | $38.12 | 1 |
| E.R. Squibb & Sons, L.L.C. | $36.56 | 2 |
| Ipsen Biopharmaceuticals, Inc | $33.18 | 1 |
| GENZYME CORPORATION | $28.46 | 1 |
| Merck Sharp & Dohme Corporation | $25.33 | 1 |
| Incyte Corporation | $24.26 | 1 |
| Exelixis Inc. | $23.48 | 1 |
| Kite Pharma, Inc. | $23.11 | 1 |
| TAIHO ONCOLOGY, INC. | $21.54 | 1 |
| AVEO Pharmaceuticals, Inc. | $20.00 | 1 |
| Acerta Pharma LLC | $19.73 | 1 |
| PharmaEssentia USA Corporation | $18.71 | 1 |
| Stemline Therapeutics Inc. | $14.33 | 1 |
| ARRAY BIOPHARMA INC | $13.21 | 1 |
By program year
Records — PY2024 (66)
Provenance & corrections
- Dataset: CMS Open Payments — General Payments
- Source: CMS Open Payments dataset (bulk file)
- Publisher of source data: Centers for Medicare & Medicaid Services
- Generated from: OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.